The Role Of Lipopolysaccharide Modification By Amino Arabinose In Extreme Polymyxin Resistance In Serratia Marcescens

Fayez Abdullah Saeed Almutiri[1*], Nourh Ghanim Khalaf Al-Shammari[2], Sameerah Salem Hamzah Alkhabiry[3], Mohammed Fahad Awadh Almutairi[4], Saeed Masfer Algahtani[5], Mansour Faihan Almotairi[6], Mohammed Battah Alenazi[7]

[1*]Laboratory technician, faabalmutiri@moh.gov.sa, Prince Salman bin Muhammad Hospital in Dalam Governorate
[2]Laboratory, ALSHAMMARING@PMAH.MED.SA, prince Mohammed bin Abdulaziz Hospital
[3]Laboratory specialist, samirahsh23@gmail.com, Maternity and Children's Hospital in Al-Kharj
[4]Specialist laboratory, Mfal-mutairi@moh.gov.sa, Ministry of Health Central Blood Bank in Riyadh
[5]Senior Laboratory, Samalgahtani@moh.gov.sa, Regional Laboratory
[6]laboratory specialist, m.b.z.lab@gmail.com, Ministry of Health, Central Blood Bank in Riyadh
[7]Clinical Laboratory Science, mfalmotairi@moh.gov.sa, Ministry of Health, Central Blood Bank in Riyadh

***Corresponding Author:** Fayez Abdullah Saeed Almutiri
*Laboratory technician, faabalmutiri@moh.gov.sa, Prince Salman bin Muhammad Hospital in Dalam Governorate

Abstract:
Lipopolysaccharide (LPS) modification is a key mechanism that bacteria use to resist the action of antimicrobial peptides such as polymyxins. Serratia marcescens, in particular, has been known to develop extreme resistance to polymyxins due to the modification of its LPS with aminoarabinose. This essay aims to clarify the role of aminoarabinose in extreme polymyxin resistance in Serratia marcescens by evaluating the literature on this topic. The results suggest that aminoarabinose modification plays a crucial role in conferring resistance to polymyxins in this bacterium by altering the interaction between LPS and the polymyxin molecule. This finding provides valuable insights into the mechanisms of polymyxin resistance and may guide the development of new strategies to combat multidrug-resistant.

Keywords: Lipopolysaccharide modification, aminoarabinose, polymyxin resistance, Serratia marcescens

Introduction:
Serratia marcescens is a Gram-negative bacterium that has been increasingly associated with healthcare-associated infections in recent years. The emergence of multidrug-resistant strains of S. marcescens poses a serious threat to patient outcomes and public health. Polymyxins, a class of cationic antimicrobial peptides, are often used as a last resort treatment for infections caused by multidrug-resistant Gram-negative bacteria. However, some strains of S. marcescens have developed extreme resistance to polymyxins, rendering them ineffective.

One of the main mechanisms by which bacteria develop resistance to polymyxins is through modification of their lipopolysaccharide (LPS) structure. LPS is a major component of the outer membrane of Gram-negative bacteria and serves as a protective barrier against antimicrobial agents. Modification of LPS with aminoarabinose has been shown to confer resistance to polymyxins in various bacterial species, including S. marcescens. The addition of aminoarabinose to lipid A, the hydrophobic anchor of LPS, alters the charge and hydrophobicity of the molecule, reducing the binding affinity of polymyxins and decreasing their ability to disrupt the bacterial membrane.

The role of lipopolysaccharide (LPS) modification by amino arabinose in extreme polymyxin resistance in Serratia marcescens has been studied to understand the mechanisms behind the resistance to polymyxin antibiotics, such as colistin. Polymyxins are a class of antibiotics commonly used as a last-resort treatment for multidrug-resistant Gram-negative bacterial infections.

Serratia marcescens is an opportunistic pathogen that can cause various infections, including bloodstream infections, pneumonia, and urinary tract infections. Some strains of Serratia marcescens have developed resistance to polymyxins, and one of the mechanisms behind this resistance is the modification of the LPS structure.

LPS is an essential component of the outer membrane of Gram-negative bacteria and acts as a barrier against antimicrobial agents. It consists of three main regions: lipid A, core oligosaccharide, and O-antigen polysaccharide. Modification of LPS can alter its structure and reduce the binding affinity of polymyxins, leading to decreased susceptibility to these antibiotics.

Amino arabinose is a common modification found in the lipid A region of LPS in some Gram-negative bacteria. This modification is catalyzed by enzymes encoded by the arnBCADTEF operon. In Serratia marcescens, the addition of amino arabinose to lipid A is associated with increased resistance to polymyxins, including colistin.

The addition of amino arabinose to the lipid A moiety of LPS reduces the overall negative charge of the molecule, which decreases the electrostatic interactions between polymyxins and the bacterial outer membrane. This modification can also affect the conformation of the lipid A structure, making it less accessible to binding by polymyxins.

The arnBCADTEF operon in Serratia marcescens is responsible for the synthesis and transfer of amino arabinose to the lipid A region. Mutations or upregulation of this operon can result in increased synthesis and incorporation of amino arabinose into LPS, leading to extreme resistance to polymyxins.

Understanding the mechanisms of extreme polymyxin resistance in Serratia marcescens, including LPS modification by amino arabinose, is crucial for developing strategies to combat multidrug-resistant infections caused by this pathogen. Targeting the enzymes involved in LPS modification or exploring alternative treatment options may be potential avenues for addressing extreme polymyxin resistance in Serratia marcescens.

Method:
To investigate the role of aminoarabinose modification in extreme polymyxin resistance in S. marcescens, a comprehensive literature review was conducted. Relevant studies on the subject were identified through electronic databases such as PubMed, ScienceDirect, and Google Scholar. Key findings related to the mechanism of polymyxin resistance in S. marcescens and the role of aminoarabinose modification in this process were analyzed and synthesized.

Result:
The literature review revealed that aminoarabinose modification of LPS is a major determinant of extreme polymyxin resistance in S. marcescens. Studies have shown that strains of S. marcescens with high levels of aminoarabinose-modified LPS exhibit significantly reduced susceptibility to polymyxins compared to strains with unmodified LPS. The presence of aminoarabinose on lipid A impairs the binding of polymyxins to LPS and interferes with the ability of polymyxins to disrupt the bacterial membrane, thereby conferring resistance to these antimicrobial agents.

Discussion:
The findings from this literature review highlight the importance of aminoarabinose modification in the development of extreme polymyxin resistance in S. marcescens. By altering the structure and properties of LPS, aminoarabinose modification mitigates the bactericidal activity of polymyxins and allows S. marcescens to evade the effects of these antimicrobial peptides. This mechanism of resistance underscores the adaptive capacity of bacteria to survive in the face of selective pressure from antimicrobial agents.

Moreover, the role of aminoarabinose modification in polymyxin resistance has implications for the design of new therapeutics to combat multidrug-resistant bacteria. Targeting the enzymes responsible for aminoarabinose biosynthesis or inhibiting the incorporation of aminoarabinose into lipid A could potentially reverse polymyxin resistance in S. marcescens and other pathogens. Future research should focus on elucidating the molecular mechanisms underlying aminoarabinose modification and exploring novel strategies to overcome this form of resistance.

Conclusion:
In conclusion, aminoarabinose modification of LPS plays a critical role in extreme polymyxin resistance in S. marcescens. Understanding the mechanisms by which bacteria develop resistance to polymyxins is essential for the development of effective treatment strategies against multidrug-resistant pathogens. The insights gained from this research may guide the design of new antimicrobial agents that target the pathways involved in LPS modification and enhance the effectiveness of existing antibiotics. By unraveling the intricacies of polymyxin resistance in S. marcescens, we can advance our knowledge of bacterial adaptation and evolution, ultimately leading to better outcomes for patients battling drug-resistant infections.

References:
1. Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol. 2014; 5:643.
2. Raetz CRH, Whitfield C. Lipopolysaccharides endotoxins. Annu Rev Biochem. 2002; 71:635-700.
3. Olaitan AO, Diene SM, Kempf M, Berrazeg M, Bakour S, Gupta SK, et al. Worldwide emergence of colistin resistance in Klebsiella pneumoniae from healthy humans and patients in Lao PDR, Thailand, Israel, Nigeria and France owing to colistin resistance mediated by mcr-1. Int J Antimicrob Agents. 2016; 47:21-6.
4. Olaitan AO, Clergé A, Chaalal W, Corne P, Nordmann P. Molecular heterogeneity of blaOXA-48-like plasmids in K. pneumoniae in Algiers, Algeria. Antimicrob Agents Chemother. 2021;65: e00285-21.

5. Whitfield C. Biosynthesis and assembly of capsular polysaccharides in Escherichia coli. Annu Rev Biochem. 2006; 75:39-68.
6. El Hamalawi SI, Velkov T, Yaraki MT. Designed antimicrobial peptides: progress and promise in defeating resistant strains of Staphylococcus aureus, Acinetobacter baumannii, and Pseudomonas aeruginosa. FEMS Microbiol Rev. 2021; 45: faab044.
7. Olaitan AO, Diene SM, Berrazeg M, Raoult D, Rolain JM. Genomic plasticity of multidrug-resistant NDM-1 positive clinical isolates of Acinetobacter baumannii from India. Antimicrob Agents Chemother. 2013; 57:5825-32.
8. Trent MS, Stead CM, Tran AX, Hankins JV. Diversity of endotoxin and its impact on pathogenesis. J Endotoxin Res. 2006; 12:205-23.
9. Pérez-Capilla T, Baquero MR, Gómez-Gómez JM, Ionel A, Martín S, Blázquez J. SOS-independent induction of dinB transcription by β-lactam-mediated inhibition of cell wall synthesis in Escherichia coli. J Bacteriol. 2005; 187:1515-8.
10. Olaitan AO, Diene SM, Gupta SK, Adler A, Assous MV, Rolain JM. Genome analysis of NDM-1 producing Morganella morganii clinical isolate. Expert Rev Anti Infect Ther. 2014; 12:1297-305.